课题基金 / 基金详情

HHSN261201200020I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Chemoprevention by Aerosolized Bexarotene in Mouse Models of All T

HHSN261201200020I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Chemoprevention by Aerosolized Bexarotene in Mouse Models of All T
HHSN261201200020I/HHSN26100007癌症预防试剂的临床前体外和体内开发测定。
批准号：
8945362
负责人：
CHINTHALAPALLY RAO
金额：
$60.71万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
项目状态：
已结题
起止时间：
2014-09-12 至 2016-09-11
来源：
https://reporter.nih.gov/project-details/8945362
关键词：
AdenocarcinomaAdverse effectsAerosolsApoptosisBexaroteneBiological MarkersBloodCell ProliferationCellsCharacteristicsChemopreventionChemopreventive AgentCholesterolClinical TrialsContractorContractsDataDevelopmentDrug FormulationsDrug KineticsEnsureGoalsGuidelinesHistopathologyHumanImmunologic MarkersIn VitroIncidenceInfiltrationInflammationLungLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMusOralOral AdministrationParticle SizePatientsPharmacodynamicsPhasePlasmaPreparationPropertyRNAReagentReverse TranscriptionSignal PathwaySignal TransductionSlideSmall Cell CarcinomaSourceSquamous cell carcinomaStructure of parenchyma of lungTissue SampleTissuesTriglyceridesWorkaerosolizedassay developmentdrug efficacyin vivomouse modelparticlepre-clinicalresearch study

项目摘要

项目成果

CHINTHALAPALLY RAO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This contract is to develop an aerosolized formulation of bexarotene; determine the chemopreventive efficacy of the aerosolized bexarotene formulation in three mouse models representative of the three major histological subtypes of lung cancer; and perform preliminary proof-of-principle pharmacokinetic/pharmacodynamic studies to assess the plasma and lung tissue levels of bexarotene, the effects of bexarotene on triglyceride and cholesterol levels in the blood plasma, and the effects of bexarotene on biomarkers of drug efficacy. The goal of the Statement of Work is to develop an aerosol formulation of bexarotene that is effective against all 3 major subtypes of lung cancer while eliminating the toxic side effects of oral bexarotene administration that would provide the necessary preclinical data to support further development to phase I/II clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING
海外基金